Joinn Laboratories (China) Co (HKSE:06127) Total Current Assets : HK$5,429 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Joinn Laboratories (China) Co's total current assets for the quarter that ended in Mar. 2025 was HK$5,429 Mil.

Joinn Laboratories (China) Co Total Current Assets Historical Data

The historical data trend for Joinn Laboratories (China) Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Total Current Assets Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

1,402.00

7,119.65

6,620.34

7,789.86

5,371.67

Joinn Laboratories (China) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															7,572.79	5,913.33	5,873.10	5,371.67	5,429.44

Joinn Laboratories (China) Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Joinn Laboratories (China) Co's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2521.122	+	372.071	+	1578.603	+	899.874
	=	5,372

Joinn Laboratories (China) Co's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2328.465	+	334.054	+	1638.777	+	1128.139
	=	5,429

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Joinn Laboratories (China) Co (HKSE:06127) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Joinn Laboratories (China) Co's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2328.465	-	1410.447	+	0.75 * 191.832	+	0.5 * 1638.777
=	1,881

Joinn Laboratories (China) Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Futu Trustee Limited	2301 Trustee
Ubs Group Ag	2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities	2102 Investment manager
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Apg Asset Management N.v.	2101 Beneficial owner
Apg Groep N.v.	2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines